Tarsus Pharmaceuticals (TARS)

The company’s lead product is XDEMVY, a prescription eye drop based on lotilaner ophthalmic solution. XDEMVY is designed to treat Demodex blepharitis, an eyelid disease associated with infestation by Demodex mites. The condition can cause redness, irritation, crusting and inflammation of the eyelids, and Tarsus positions the product as a targeted therapy that addresses the underlying mite infestation rather than only managing symptoms.

Beyond its commercial eye-care franchise, Tarsus is developing additional product candidates that use its expertise in parasitic and inflammatory disease biology. Its pipeline has included TP-04 for ocular rosacea, a condition linked to inflammation around the eyes, and TP-05, an oral program being studied for potential prevention of Lyme disease and for reducing malaria transmission in communities.

As a listed biotechnology stock, Tarsus is shaped by the execution risks common to emerging pharma companies: prescription uptake, physician awareness, payer coverage, clinical trial outcomes and regulatory progress. Its investment profile is also closely tied to the size of the Demodex blepharitis market and the company’s ability to extend its technology platform into new indications. Tarsus stands out for concentrating on diseases where parasites or mites play a direct role and for bringing a targeted therapeutic approach to areas of eye care that have often lacked dedicated treatments.